Back to search

National and Kapodistrian University of Athens

Η εφαρμογή της μεταγραφομικής (transcriptomics) για την ανεύρεση προγνωστικών δεικτών ανταπόκρισης στη θεραπεία της ελκώδους κολίτιδας με Ustekinumab

Abstract

dc:description

Introduction: Optimizing treatment with biological agents is an ideal goal for patients with ulcerative colitis (UC). Recent data suggest that mucosal inflammation patterns and serum cytokine profiles differ between patients who respond and those who do not. Ustekinumab, a monoclonal antibody targeting the p40 subunit of interleukin (IL)-12 and IL-23, has shown promise, but predicting treatment response remains a challenge. We aimed to identify prognostic markers of response to ustekinumab in patients with active UC, utilizing information from their mucosal transcriptome. Methods: We performed a prospective observational study of 36 UC patients initiating treatment with ustekinumab. Colonic biopsies were obtained prior to treatment initiation for gene expression analysis using RT-qPCR (Reverse Transcription quantitative Polymerase Chain Reaction) with a panel of 84 predefined genes related to inflammation and autoimmunity. A differential gene expression analysis (DGEA), correlation analysis, and network centrality analysis on co-expression networks were performed to identify potential biomarkers. Additionally, machine learning (ML) models were employed to predict treatment response based on gene expression data. Results: Seven genes, including BCL6, CXCL5, and FASLG, were significantly upregulated, while IL23A and IL23R were downregulated in non-responders compared to responders. The co-expression analysis revealed distinct patterns between responders and non-responders, with key genes like BCL6 and CRP highlighted in responders and CCL11 and CCL22 in nonresponders. The ML algorithms demonstrated a high predictive power, emphasizing the significance of the IL23R, IL23A, and BCL6 genes. Conclusions: Our study identifies potential biomarkers associated with ustekinumab response in UC patients, shedding light on its underlying mechanisms and variability in treatment outcomes. Integrating transcriptomic approaches, including gene expression analyses and ML, offers valuable insights for personalized treatment strategies and highlights avenues for further research to enhance therapeutic outcomes for patients with UC.

Degree

thesis:*
Grantor dc:publisher
National and Kapodistrian University of Athens
Year dc:date
2025

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Koustenis, Kanellos-Rafail
  • Κουστένης, Κανέλλος-Ραφαήλ

Subjects

dc:subject × 15

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/60088

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Koustenis, Kanellos-Rafail; Κουστένης, Κανέλλος-Ραφαήλ. Η εφαρμογή της μεταγραφομικής (transcriptomics) για την ανεύρεση προγνωστικών δεικτών ανταπόκρισης στη θεραπεία της ελκώδους κολίτιδας με Ustekinumab. National and Kapodistrian University of Athens, 2025. http://hdl.handle.net/10442/hedi/60088